The real news here is what hiring a lead investigator means. It means that Phase 2 trials of a medical marijuana product to treat MS pain and spasticity are closer to beginning. In fact, MMJ BioScience hopes to start them, with several hundred patients, in early 2018.
MMJ BioScience, an affiliate of medical cannabis research company MMJ International Holdings, has hired a principal investigator to lead clinical trials exploring potential therapeutic applications of cannabinoids in progressive multiple sclerosis (MS).
Dr. Bianca Weinstock-Guttman, a neurology professor at the State University of New York at Buffalo, is executive director of the New York State Multiple Sclerosis Consortium. She will lead Phase 2 clinical trials, which have already been cleared